Study S002483

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06500299
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 180
Start: 2024-07-15
Primary completion: 2024-10-30
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Overweight and Obesity
Interventions: DRUG:HDM1002 100 mg QD; DRUG:HDM1002 200 mg QD 12weeks; DRUG:HDM1002 400 mg QD 12weeks; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Percentage Change From Baseline in Body Weight at Week 12 [Baseline, Week 12]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0033124	2609-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1 Receptor Agonist HDM1002 in Chinese Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial XIAOYING LI, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06500299